Benefits of statins in elderly subjects without established cardiovascular disease: A meta-analysis

Journal of the American College of Cardiology

Volumn 62, Issue 22, 2013, Pages 2090-2099

  Savarese, Gianluigi ^a   Gotto Jr , Antonio M ^b   Paolillo, Stefania ^a   D'Amore, Carmen ^a   Losco, Teresa ^a   Musella, Francesca ^a   Scala, Oriana ^a   Marciano, Caterina ^a   Ruggiero, Donatella ^a   Marsico, Fabio ^a   De Luca, Giuseppe ^c   Trimarco, Bruno ^a   Perrone Filardi, Pasquale ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

cardiovascular risk; elderly; primary prevention; statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO;

AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DRUG EFFICACY; ELDERLY CARE; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS;

EID: 84888357522     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2013.07.069     Document Type: Article

References (42)

1. V.L. Roger, A.S. Go, D.M. Lloyd-Jones on behalf of the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Heart disease and stroke statistics - 2012 update: a report from the American Heart Association Circulation 125 2012 e2 e220
2. C. Baigent, L. Blackwell, J. Emberson for the Cholesterol Treatment Trialists' (CTT) Collaboration Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
3. Z. Reiner, A.L. Catapano, G. De Backer European Association for Cardiovascular Prevention & Rehabilitation ESC/EAS guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS) Eur Heart J 32 2011 1769 1818
4. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) JAMA 285 2001 2486 2497
5. J.J. Brugts, T. Yetgin, and S.E. Hoeks The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials BMJ 338 2009 b2376
6. P.M. Ridker, A. Pradhan, J.G. MacFadyen, P. Libby, and R.J. Glynn Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Lancet 380 2012 565 567
7. J. Shepherd, G.J. Blauw, M.B. Murphy PROspective Study of Pravastatin in the Elderly at Risk Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
8. J. Afilalo, G. Duque, and R. Steele Statins for secondary prevention in elderly patients: a hierarchical Bayesian meta-analysis J Am Coll Cardiol 51 2008 37 45
9. D. Moher, A. Liberati, J. Tetzlaff, D.G. Altman for the PRISMA Group Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement J Clin Epidemiol 62 2009 1006 1012
10. D. Atkins, D. Best, and P.A. Briss Grading quality of evidence and strength of recommendations (abstract) BMJ 328 2004 1490
11. S. Sharp, and J. Sterne Meta-analysis STB Reprints 7 1998 100 108
12. A. Whitehead Meta-Analysis of Controlled Clinical Trials 2002 John Wiley & Sons Inc. Chichester, England
13. M.J. Bradburn, J.J. Deeks, J.A. Berlin, and A. Russell Localio Much ado about nothing: a comparison of the performance of meta-analytical methods with rare events Stat Med 26 2007 53 77
14. A. Tobias Assessing the influence of a single study in meta-analysis STB 47 1999 15 17
15. S.J. Sharp Meta-analysis regression STB 42 1998 16 22
16. P. Costanzo, P. Perrone-Filardi, and M. Petretta Calcium channel blockers and cardiovascular outcomes: a meta-analysis of 175,634 patients J Hypertens 27 2009 1136 1151
17. S.G. Thompson, and S.J. Sharp Explaining heterogeneity in meta-analysis: a comparison of methods Stat Med 18 1999 2693 2708
18. J.L. Peters, A.J. Sutton, D.R. Jones, K.R. Abrams, and L. Rushton Comparison of two methods to detect publication bias in meta-analysis JAMA 295 2006 676 680
19. M.A. Albert, E. Danielson, N. Rifai, P.M. Ridker for the PRINCE Investigators Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70
20. J.C. LaRosa, W. Applegate, and J.R. Crouse 3rd Cholesterol lowering in the elderly. Results of the Cholesterol Reduction in Seniors Program (CRISP) pilot study Arch Intern Med 154 1994 529 539
21. J.R. Crouse 3rd, J.S. Raichlen, and W.A. Riley Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial JAMA 297 2007 1344 1353
22. Heart Protection Study Collaborative Group MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
23. C.D. Furberg, H.P. Adams Jr., W.B. Applegate Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group Effect of lovastatin on early carotid atherosclerosis and cardiovascular events Circulation 90 1994 1679 1687
24. R.H. Knopp, M. d'Emden, J.G. Smilde, and S.J. Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
25. J.R. Downs, M. Clearfield, and S. Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study JAMA 279 1998 1615 1622
26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
27. E. Bruckert, M. Lièvre, and P. Giral Short-term efficacy and safety of extended-release fluvastatin in a large cohort of elderly patients Am J Geriatr Cardiol 12 2003 225 231
28. H.A. Neil, D.A. DeMicco, and D. Luo Analysis of efficacy and safety in patients aged 65-75 years at randomization: Collaborative Atorvastatin Diabetes Study (CARDS) Diabetes Care 29 2006 2378 2384
29. R.J. Glynn, W. Koenig, B.G. Nordestgaard, J. Shepherd, and P.M. Ridker Rosuvastatin for primary prevention in older persons with elevated C-reactive protein and low to average low-density lipoprotein cholesterol levels: exploratory analysis of a randomized trial Ann Intern Med 152 2010 488 496
30. D.J. Collier, N.R. Poulter, and B. Dahlöf Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm J Hypertens 29 2011 592 599
31. N. Nakaya, K. Mizuno, and Y. Ohashi Low-dose pravastatin and age-related differences in risk factors for cardiovascular disease in hypercholesterolaemic Japanese: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA study) Drugs Aging 28 2011 681 692
32. G. Rose Strategy of prevention: lessons from cardiovascular disease Br Med J (Clin Res Ed) 282 1981 1847 1851
33. F. Taylor, M.D. Huffman, and A.F. Macedo Statins for the primary prevention of cardiovascular disease Cochrane Database Syst Rev 1 2013 CD004816
34. E.J. Mills, B. Rachlis, P. Wu, P.J. Devereaux, P. Arora, and D. Perri Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients J Am Coll Cardiol 52 2008 1769 1781
35. B. Mihaylova, J. Emberson, L. Blackwell Cholesterol Treatment Trialists' (CTT) Collaborators The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials Lancet 380 2012 581 590
36. T. Pellegrino, G. Storto, and P.P. Filardi Relationship between brachial artery flow-mediated dilation and coronary flow reserve in patients with peripheral artery disease J Nucl Med 46 2005 1997 2002
37. P. Perrone-Filardi, A. Cuocolo, and G. Brevetti Relation of brachial artery flow-mediated vasodilation to significant coronary artery disease in patients with peripheral arterial disease Am J Cardiol 96 2005 1337 1341
38. P. Perrone-Filardi, F. Musella, and G. Savarese Coronary computed tomography: current role and future perspectives for cardiovascular risk stratification Eur Heart J Cardiovasc Imaging 13 2012 453 458
39. P. Costanzo, P. Perrone-Filardi, and E. Vassallo Does carotid intima-media thickness regression predict reduction of cardiovascular events? A meta-analysis of 41 randomized trials J Am Coll Cardiol 56 2010 2006 2020
40. P. Perrone-Filardi, S. Achenbach, and S. Möhlenkamp Cardiac computed tomography and myocardial perfusion scintigraphy for risk stratification in asymptomatic individuals without known cardiovascular disease: a position statement of the Working Group on Nuclear Cardiology and Cardiac CT of the European Society of Cardiology Eur Heart J 32 2011 1986 1993
41. B.S. Ferket, B.J. van Kempen, and J. Heeringa Personalized prediction of lifetime benefits with statin therapy for asymptomatic individuals: a modeling study PLoS Med 9 2012 e1001361
42. M. Petretta, P. Costanzo, P. Perrone-Filardi, and M. Chiariello Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis Int J Cardiol 138 2010 25 31